Patents by Inventor Geoffrey T. Yarranton

Geoffrey T. Yarranton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EphA3 antibodies for the treatment of solid tumors
    Patent number: 8637016
    Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of solid tumors.
    Type: Grant
    Filed: March 10, 2008
    Date of Patent: January 28, 2014
    Assignees: KaloBios Pharmaceuticals, Inc., Monash University, Ludwig Institute for Cancer Research Limited
    Inventors: Martin Lackmann, Andrew Mark Scott, Christopher R. Bebbington, Geoffrey T. Yarranton, Carmelina Murone, Catherine To
  • Methods of treating dementia using a GM-CSF antagonist
    Patent number: 8398972
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of a patient that has Alzheimer's disease or vascular dementia, or is at risk for developing Alzheimer's disease. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody and pharmaceutical compositions comprising such antagonists.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: March 19, 2013
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
  • ANTI-EMR1 ANTIBODIES
    Publication number: 20130064826
    Abstract: The invention provides anti-EMR1 antibodies and methods of using such antibodies to treat EMR1-related diseases.
    Type: Application
    Filed: May 25, 2012
    Publication date: March 14, 2013
    Inventors: Kenneth Luehrsen, Mark Baer, Christopher R. Bebbington, David Martinez, Varghese Palath, Swathi Sujatha-Bhaskar, Nenad Tomasevic, Jason Williams, Geoffrey T. Yarranton
  • METHODS OF TREATING HEMATOLOGICAL PROLIFERATIVE DISORDERS BY TARGETING EPHA3 EXPRESSED ON ABERRANT VASCULATURE IN BONE MARROW
    Publication number: 20130039907
    Abstract: The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders.
    Type: Application
    Filed: August 10, 2012
    Publication date: February 14, 2013
    Applicant: KaloBios Pharmaceuticals Inc.
    Inventors: Geoffrey T. Yarranton, Varghese Palath, Christopher R. Bebbington, Mark Baer
  • Secretion of antibodies without signal peptides from bacteria
    Publication number: 20120309055
    Abstract: The present invention is directed generally to compositions and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from prokaryotes without the need for a signal peptide through making use of mutant host strains with altered secretory properties. In particular, the invention provides host cells and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from bacteria without the need for a signal peptide and provides diverse libraries of antibody sequence resulting from such methods. The invention additionally provides diverse libraries.
    Type: Application
    Filed: May 7, 2012
    Publication date: December 6, 2012
    Applicant: KaloBios Pharmaceuticals Inc.
    Inventors: Geoffrey T. Yarranton, Christopher R. Bebbington
  • ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
    Publication number: 20120213776
    Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Application
    Filed: April 30, 2012
    Publication date: August 23, 2012
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton
  • Secretion of antibodies without signal peptides from bacteria
    Patent number: 8211648
    Abstract: The present invention is directed generally to compositions and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from prokaryotes without the need for a signal peptide through making use of mutant host strains with altered secretory properties. In particular, the invention provides host cells and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from bacteria without the need for a signal peptide and provides diverse libraries of antibody sequence resulting from such methods. The invention additionally provides diverse libraries.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: July 3, 2012
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Geoffrey T. Yarranton, Christopher R. Bebbington
  • Antibodies to granulocyte-macrophage colony-stimulating factor
    Patent number: 8168183
    Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: May 1, 2012
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton
  • Antibodies to the PcrV Antigen of Pseudomonas aeruginosa
    Publication number: 20120020986
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Application
    Filed: October 11, 2011
    Publication date: January 26, 2012
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
  • METHODS OF TREATING BONE-LOSS DISORDERS USING A GM-CSF ANTAGONIST
    Publication number: 20120009191
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of bone loss disorders, such as osteopenia. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, to a patient that has a bone loss disorder and pharmaceutical compositions comprising such antagonists.
    Type: Application
    Filed: July 8, 2011
    Publication date: January 12, 2012
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton
  • DETECTION OF EPHA3 AS A MARKER OF THE PRESENCE OF A SOLID TUMOR
    Publication number: 20110318304
    Abstract: The invention provides methods and compositions for detecting non-hematopoietic, non-tumor EphA3-expressing cells in cancer patients and for monitoring the prognosis of patients using EphA3.
    Type: Application
    Filed: June 20, 2011
    Publication date: December 29, 2011
    Inventors: Martin Lackmann, Andrew Mark Scott, Catherine To, Christopher R. Bebbington, Geoffrey T. Yarranton, Mark Baer, Varghese Palath
  • Methods of treating heart failure using an anti-GM-CSF antibody
    Patent number: 8075885
    Abstract: This invention relates to methods of treating a patient suffering from heart failure, or a patient at risk for heart failure, using a GM-CSF antagonist.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: December 13, 2011
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton
  • Antibodies to the PcrV antigen of
    Patent number: 8044181
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Grant
    Filed: December 1, 2008
    Date of Patent: October 25, 2011
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
  • Enzyme-cleavable prodrug compounds
    Patent number: 8034787
    Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavable sequences within the conjugate and methods of treating patients with prodrugs of the invention.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: October 11, 2011
    Assignee: Medarex, Inc.
    Inventors: Vincent Dubois, Ann Marie Fernandez, Sanjeev Gangwar, Evan Lewis, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey T. Yarranton
  • GENERATION OF ANTIBODIES TO AN EPITOPE OF INTEREST
    Publication number: 20110245100
    Abstract: The invention provides methods of obtaining antibodies to an epitope of interest based on an anti-hapten focused library.
    Type: Application
    Filed: April 4, 2011
    Publication date: October 6, 2011
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Geoffrey T. Yarranton, Kenneth Luehrsen, Christopher R. Bebbington, Nenad Tomasevic
  • Antibody specificity transfer using minimal essential binding determinants
    Patent number: 7981843
    Abstract: The present invention provides methods of making antibodies having the binding specificity of a reference antibody. Antibodies generated by the methods of the inventions have at least one minimal essential binding specificity determinant from a heavy chain or light chain CDR3 from the reference antibody. The method can be used, e.g., in humanization procedures. The invention also provides libraries and antibodies made in accordance with the methods.
    Type: Grant
    Filed: January 20, 2005
    Date of Patent: July 19, 2011
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Peter Flynn, Kenneth Luehrsen, Robert F. Balint, Jeng-Horng Her, Christopher R. Bebbington, Geoffrey T. Yarranton
  • METHODS FOR THE THERAPY OF INFLAMMATORY BOWEL DISEASE USING A TYPE-1 INTERFERON ANTAGONIST
    Publication number: 20110165158
    Abstract: Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD), including Celiac Disease, Crohn's Disease, and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such as anti-type 1 interferon receptor antibody antagonists and fragments thereof, as well as polypeptides and small molecules that inhibit the interaction of type 1 interferon with its receptor (IFNAR).
    Type: Application
    Filed: March 17, 2011
    Publication date: July 7, 2011
    Applicant: MEDAREX, INC.
    Inventors: Lesley B. Pickford, Christopher R. Bebbington, Geoffrey T. Yarranton, David King
  • METHOD OF TREATING A STAPHYLOCOCCUS INFECTION IN A PATIENT HAVING A LOW-LEVEL PATHOGENIC PSEUDOMONAS AERUGINOSA INFECTION
    Publication number: 20110165172
    Abstract: This invention provides methods of treating patients having a Staphylococcus infection where the patient also has a low level of Pseudomonas aeruginosa. The methods comprise administering an antagonist of the Pseudomonas Type III Secretion System, e.g., an anti-PcrV antibody antagonist.
    Type: Application
    Filed: December 21, 2010
    Publication date: July 7, 2011
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventor: Geoffrey T. Yarranton
  • Antibodies to EphA3
    Publication number: 20110123549
    Abstract: The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Application
    Filed: October 14, 2010
    Publication date: May 26, 2011
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Kenneth Luehrsen, David Martinez, Christina Yi, Christopher R. Bebbington, Geoffrey T. Yarranton
  • Methods for the therapy of Inflammatory Bowel Disease using a type-1 interferon antagonist
    Patent number: 7939076
    Abstract: Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD), including Celiac Disease, Crohn's Disease, and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such as anti-type 1 interferon receptor antibody antagonists and fragments thereof, as well as polypeptides and small molecules that inhibit the interaction of type 1 interferon with its receptor (IFNAR).
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: May 10, 2011
    Assignee: Medarex, Inc.
    Inventors: Lesley B. Pickford, Christopher R. Bebbington, Geoffrey T. Yarranton, David King